Kymera Therapeutics (KYMR) Accounts Payables (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Accounts Payables data on file, last reported at $12.8 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $12.8 million, up 25.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.8 million (up 25.1% YoY), and the FY2025 annual result was $4.0 million, down 32.96% from the prior year.
• Accounts Payables improved to $12.8 million in Q1 2026 per KYMR's latest filing, from $4.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.8 million in Q1 2026 and troughed at $2.4 million in Q2 2022.
• A 5-year average of $6.0 million and a median of $6.0 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables sank 70.97% in 2022, then soared 152.55% in 2023.
• A 5-year view of Accounts Payables shows it stood at $4.3 million in 2022, then soared by 63.21% to $7.1 million in 2023, then fell by 15.35% to $6.0 million in 2024, then plunged by 32.96% to $4.0 million in 2025, then soared by 219.78% to $12.8 million in 2026.
• Business Quant data shows KYMR's Accounts Payables at $12.8 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.